ETON vs. CLSD, ACRS, ORMP, ANIX, MIST, ADAG, BYSI, PRPH, ONCY, and IOBT
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Clearside Biomedical (CLSD), Aclaris Therapeutics (ACRS), Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Adagene (ADAG), BeyondSpring (BYSI), ProPhase Labs (PRPH), Oncolytics Biotech (ONCY), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Eton Pharmaceuticals (NASDAQ:ETON) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
In the previous week, Clearside Biomedical had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 14 mentions for Clearside Biomedical and 11 mentions for Eton Pharmaceuticals. Clearside Biomedical's average media sentiment score of 0.13 beat Eton Pharmaceuticals' score of 0.12 indicating that Clearside Biomedical is being referred to more favorably in the news media.
Eton Pharmaceuticals has higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eton Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are owned by institutional investors. 13.2% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 9.8% of Clearside Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Clearside Biomedical received 270 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 67.05% of users gave Clearside Biomedical an outperform vote while only 62.22% of users gave Eton Pharmaceuticals an outperform vote.
Eton Pharmaceuticals has a net margin of 2.66% compared to Clearside Biomedical's net margin of -413.73%. Eton Pharmaceuticals' return on equity of 5.58% beat Clearside Biomedical's return on equity.
Eton Pharmaceuticals currently has a consensus price target of $9.00, suggesting a potential upside of 162.39%. Clearside Biomedical has a consensus price target of $4.75, suggesting a potential upside of 280.00%. Given Clearside Biomedical's higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than Eton Pharmaceuticals.
Summary
Eton Pharmaceuticals beats Clearside Biomedical on 9 of the 17 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
